# A Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Fruquintinib in the Treatment of Immunodominant pMMR/MSS Metastatic Colorectal Cancer That Has Failed Second-line or Above Treatment

> **NCT07229872** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Harbin Medical University** · enrollment: 18 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Aipalolitovorelizumab
- **DRUG:** Fruquintinib

## Key facts

- **NCT ID:** NCT07229872
- **Lead sponsor:** Harbin Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07229872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07229872, "A Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Fruquintinib in the Treatment of Immunodominant pMMR/MSS Metastatic Colorectal Cancer That Has Failed Second-line or Above Treatment". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07229872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*